Understanding Artificial Pancreas Systems: Results from a 24-Month Trial

Related and Discussions

Subscribe now for the latest breakthroughs, expert insights, and cutting-edge updates in diabetes care—delivered straight to your inbox.

Stay informed. Stay ahead.

HbA1c effects were inconsistent across trials. One study showed a meaningful reduction of 1.18% after 12 weeks of PBMT via laser watch, but most other trials reported no significant between-group differences or only transient effects. The wide variation in PBMT protocols and outcomes makes it difficult to draw firm conclusions about glycemic benefits.

Meta-analysis of 3 trials showed a small but statistically significant improvement in clinical attachment level of 0.21 mm when PBMT was used as an adjunct to standard periodontal therapy. While the effect was consistent across studies, the magnitude of benefit is below the 1 mm threshold typically considered clinically meaningful for long-term periodontal stability.

Pooled results from 3 trials showed a reduction in probing depth of 0.25 mm when PBMT was added to scaling and root planing. The effect was statistically significant with low heterogeneity between studies, but the clinical relevance of such a small improvement is uncertain when used as a standalone metric.

One trial of monochromatic infrared energy therapy over 12 weeks showed substantial pain reduction of 5.1 points on the visual analog scale, exceeding the 1.7-2 point threshold for clinical meaningfulness. Quality of life scores also improved by 15 points. However, these symptomatic improvements were not accompanied by structural nerve regeneration as measured by intraepidermal nerve fiber density.

Quality of life assessed via the Norfolk Quality of Life-Diabetic Neuropathy questionnaire improved by 15 points after 12 weeks of PBMT for painful diabetic neuropathy. This improvement tracked with pain reduction and suggests meaningful symptomatic benefit, though effects were observed in only one trial.

Previous reviews of photobiomodulation for gum disease found similar small improvements when used alongside standard periodontal therapy. Studies in people without diabetes also reported modest benefits for gum health. The evidence for metabolic effects in diabetes is newer and less consistent. Animal studies suggest potential mechanisms through improved mitochondrial function and glucose uptake, but human trials have not reliably shown these benefits.

The certainty of evidence is low due to small sample sizes in individual trials (10-80 participants each), substantial differences in how PBMT was delivered, and incomplete reporting. The gum health findings come from only 3 studies with consistent results, while blood sugar and inflammatory effects were measured differently across trials, making it hard to draw firm conclusions.

Photobiomodulation may produce small improvements in gum health when used alongside standard periodontal treatment, but the clinical importance of 0.2-0.3 mm changes is unclear.

Effects on blood sugar control are inconsistent, with most trials showing no benefit and one trial showing meaningful improvement.

Short-term symptom relief was seen for nerve pain, but structural nerve improvements were not observed.

The evidence suggests photobiomodulation may offer modest support for gum health in diabetes, but effects are small and may not be clinically meaningful on their own.

For blood sugar control, the findings are too inconsistent to draw reliable conclusions, with most trials showing little to no benefit.

Symptom relief for nerve pain appears promising, but this is based on a single trial and did not correspond with nerve regeneration.

The wide variation in treatment approaches makes it impossible to identify optimal parameters or predict who might benefit most.

Photobiomodulation therapy (also called low-level laser therapy) uses red or near-infrared light applied to skin or tissues. The included trials used different approaches: some applied light to leg muscles, some to gums, some to wrist blood vessels, and some to oral tissues. Light wavelengths ranged from 630-1064 nanometers, power from 5 to 4000 milliwatts, and treatment sessions from a single application to 36 sessions over 12 weeks. Most trials compared PBMT to sham devices (device turned off) or to standard diabetes care alone.

Photobiomodulation therapy, Low-level laser therapy, Light therapy, Phototherapy

Wevers A, San Roman-Mata S, Navarro-Ledesma S, Pruimboom L. Effects of Photobiomodulation on Metabolic, Inflammatory, and Neurological Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2026;27(1):440. doi:10.3390/ijms27010440

The analysis included 10 trials with sample sizes ranging from 10 to 80 participants. For gum health, combining 3 trials showed small improvements in clinical attachment level (0.21 mm better) and probing depth (0.25 mm better), but no change in plaque levels. For blood sugar control, only one trial of 60 people found meaningful HbA1c reductions after 12 weeks; other trials showed no effect or short-term changes that did not last. For inflammation, one trial reported lower IL-6 levels after treatment. For nerve pain, one trial found substantial symptom relief over 12 weeks, though nerve fiber density did not improve.

Photobiomodulation shows small gum health benefits but inconsistent effects on blood sugar and inflammation in type 2 diabetes.

The included trials varied widely in how photobiomodulation was applied—different light wavelengths, doses, treatment durations, and body sites—making it difficult to identify what works best. Most studies were small and followed participants for only weeks to months, so long-term effects remain unknown. The analysis was limited to English-language publications and may have missed relevant studies in other languages.

Gum attachment level → ↓ (small improvement)

HbA1c → Mixed → (unclear - one positive trial, most showed no effect)

Nerve pain symptoms → ↓ (moderate short-term improvement)

Photobiomodulation therapy ameliorates hyperglycemia and insulin resistance

Diabetes in spotlight: Current knowledge and perspectives of photobiomodulation

NIH National Institute of Diabetes and Digestive and Kidney Diseases

Researchers searched five medical databases through June 2025 for randomized trials testing photobiomodulation therapy in adults with type 2 diabetes. They included studies that compared PBMT to sham treatment, usual care, or no intervention. Two reviewers independently screened studies, extracted data, and assessed quality using standard tools. For outcomes measured consistently across studies, they combined results using random-effects meta-analysis. Studies with different measurement methods or insufficient data were summarized narratively.

Photobiomodulation shows small periodontal benefits but mixed systemic effects in type 2 diabetes

This systematic review examined photobiomodulation therapy (PBMT) in adults with type 2 diabetes across 10 randomized trials. Researchers tested whether PBMT could improve blood sugar control, reduce inflammation, or help with nerve damage. The main results show small improvements in gum health (0.2-0.3 mm in clinical measures), but effects on blood sugar and inflammation were inconsistent. One trial found meaningful HbA1c reductions, but most others showed no benefit. PBMT provided short-term symptom relief for painful neuropathy but did not improve nerve structure. Overall, effects varied widely across studies, and benefits appear modest at best.

Individual trials were small, with most including fewer than 50 people, so results may not be reliable.

Treatment approaches varied dramatically across studies, making it difficult to know what specific protocol might work.

Most studies lasted only weeks to a few months, so long-term safety and effectiveness are unknown.

The review authors conclude that photobiomodulation should not yet be considered an evidence-based therapy for diabetes management.

Systematic review of 10 trials with 292-362 adults with type 2 diabetes testing light therapy effects

Adults with type 2 diabetes who have gum disease or painful diabetic neuropathy. Results come from small studies with participants mainly in their 40s to 60s from Brazil, Egypt, India, Kosovo, Saudi Arabia, and Turkey.

Adults with type 2 diabetes who are interested in complementary therapies. The most relevant findings apply to people with gum disease or painful nerve damage from diabetes. Effects may not apply to everyone, as individual trials showed different results.

Photobiomodulation shows small periodontal benefits but mixed systemic effects in type 2 diabetes

Study at a glance

Main effects

Evidence Suggest

Who this applies to

Keep in Mind

Between the Lines

Unlock Full Analysis

Journal Reference

No ads. No tracking.

Secure & private

Always up to date